Clearside Biomedical Inc (CLSD) Given Consensus Recommendation of “Hold” by Brokerages

Share on StockTwits

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have received an average rating of “Hold” from the eleven brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.83.

CLSD has been the topic of several analyst reports. Cowen reissued a “hold” rating on shares of Clearside Biomedical in a research note on Tuesday, January 22nd. ValuEngine cut Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th.

Shares of CLSD stock traded down $0.04 during trading hours on Friday, hitting $1.34. The stock had a trading volume of 719,800 shares, compared to its average volume of 1,164,416. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.22. Clearside Biomedical has a one year low of $0.99 and a one year high of $15.33.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in Clearside Biomedical by 2.3% during the third quarter. BlackRock Inc. now owns 1,903,108 shares of the company’s stock worth $11,704,000 after acquiring an additional 43,160 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Clearside Biomedical by 2.2% during the third quarter. Vanguard Group Inc. now owns 1,255,662 shares of the company’s stock valued at $7,723,000 after buying an additional 27,178 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Clearside Biomedical by 2.2% during the third quarter. Vanguard Group Inc now owns 1,255,662 shares of the company’s stock valued at $7,723,000 after buying an additional 27,178 shares during the last quarter. Sphera Funds Management LTD. grew its stake in shares of Clearside Biomedical by 2.6% during the fourth quarter. Sphera Funds Management LTD. now owns 1,185,124 shares of the company’s stock valued at $1,268,000 after buying an additional 30,434 shares during the last quarter. Finally, AWM Investment Company Inc. grew its stake in shares of Clearside Biomedical by 31.6% during the third quarter. AWM Investment Company Inc. now owns 875,126 shares of the company’s stock valued at $5,382,000 after buying an additional 210,131 shares during the last quarter. 56.57% of the stock is currently owned by institutional investors.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Featured Article: What are catch-up contributions?

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply